Ovarian cancer constituted the eighth most frequently diagnosed neoplasm in females and the third most commonly occurring gynecological malignancy globally in 2020.1,2 It is classified into five major histologic subtypes, with high-grade serous carcinoma (HGSC) being the most prevalent.3 Standard of care primary treatment involves surgery and platinum-based chemotherapy.3,4 Advanced-stage patients also receive bevacizumab, a monoclonal antibody (mAb) targeting vascular endothelial growth factor (VEGF). Here, VEGFA is linked to ovarian carcinoma.